Insider buying last 90 days
No open-market insider purchases were filed for VTRS in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
Viatris moved on third-quarter results and guidance this week. The company reported nearly flat third-quarter revenue of $3.7495 billion, with adjusted EPS up 6%, while the U.S. GAAP net loss widened due to a higher income tax provision. Despite the revenue miss, Viatris beat EBITDA forecasts on lower operating expenses and raised its 2026 guidance midpoints across key financial metrics. Analyst reaction followed, with Jefferies raising its price target to $22 from $20 while maintaining a Buy rating, and JP Morgan lifting its target to $21 from $20 while keeping a Neutral rating. Commentary also pointed to Viatris's strategic shift toward complex generics, new launches, pipeline progression and cost savings for long-term growth.
Viatris shares closed at $20.49, up 2.9%, sitting above both the 50-day average of $17.78 and the 200-day average of $16.09, within the 52-week range topped by $20.53. The stock has returned 16.2% over one month and 102.7% over one year. The GekkoIndex reads 43.2, placing the stock in the Distribution zone, down 8.1 over five days. Price sits 4.7% above Gekko Fair Value of $19.57.
The next earnings date is 25 February 2027, 102 days away, outside a typical 20-trading-day hold. No insider, Congress, or unusual options activity (30-day window) appears in the current period, though four billionaire holders are noted. Seasonality from this calendar point has averaged +2.2% over the next 20 trading days across 5 years, rising in 3 of them. Analyst consensus across 9 firms shows 5 buy, 3 hold, 1 sell, with a consensus target of $20.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
Viatris scores 2 supportive, 2 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive2 mixed1 headwind
Above 50 and 200-day
Close $20.82 is above the 50-day ($18.11) and 200-day ($16.24) averages, and the 50-day is above the 200-day.
See the chart46.3, Neutral
Reading 46.3 is in the Neutral zone.
See the GekkoIndex7.8% above
Price is 7.8% above Gekko Fair Value (more than 5% above).
See fair valueNo data
No insider, Congress or unusual options activity in the window.
See smart moneyReports in 102 days
Next report Feb 25, 2027, 102 days away — outside a typical 20-trading-day hold.
See earnings+1.5% on average
From this point in the calendar, the next 20 trading days averaged +1.5% over 5 years, rising in 2 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Viatris closed at $20.82 on Nov 13, 2026, +89.1% over the past year, inside a 52-week range of $10.15 to $21.20.
Use the left and right arrow keys to read daily values.
Put VTRS on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Viatris makes and supplies medicines and related health products worldwide, spanning branded drugs, generic and complex generic versions, biosimilars, and active pharmaceutical ingredients. Its medicines cover a wide span of conditions, from long-term illnesses to infectious disease, with biosimilar treatments aimed at areas such as cancer care, immune disorders, hormone conditions, eye disease, and skin conditions. Familiar names in its lineup include Lyrica, Lipitor, EpiPen, Viagra, and Celebrex, alongside biosimilar products like Fulphila, Ogivri, Hulio, and SEMGLEE.
The company is organized into four regional segments covering developed markets, Greater China, Japan/Australia/New Zealand, and emerging markets. It sells medicines in forms ranging from pills and injectables to raw ingredients, reaching pharmacies, wholesalers, hospitals, governments, and insurers through channels that include mail-order and specialty pharmacy networks. Beyond selling drugs, it offers services such as diagnostic clinics, health education, and digital tools, and it works with partners including Biocon, Theravance Biopharma, and Fujifilm Kyowa Kirin Biologics on development and licensing.
Viatris was founded in 1961 and is headquartered in Canonsburg, Pennsylvania. Its shares are listed on the NASDAQ under the ticker VTRS.
Viatris’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 46.3, in the Neutral zone, down 0.9 points over five sessions.
Down 0.9 points over five sessions.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 32 | +1.0% | −0.2% | ||
| Accumulation | 205 | +0.1% | +0.4% | ||
| Neutral (current zone) | 402 | +0.6% | +3.3% | ||
| Distribution | 55 | +0.7% | −0.7% | ||
| Selling | 8 | Too few readings yet | |||
Average VTRS share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
Viatris trades 7.8% above Gekko Fair Value of $19.31, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what Viatris shares are worth, recalculated every trading day.
$19.31
Gekko Fair Value, Nov 14, 2026
7.8% Overvalued
At the end of Aug 2026 the price was 15.4% below the estimate.
No open-market insider purchases were filed for Viatris, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for VTRS in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in VTRS were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Viatris has been buying back its own shares.
From company filings.
1of the funds Gekko tracks holds VTRS.
Viatris reports on Feb 25, 2027, before the open (102 days away), and beat the EPS estimate in 7 of its last 8 reports.
Feb 25, 2027
Expected before the open, 102 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 6, 2026 | $0.69 est $0.62 | $3.76B est $3.68B | −6.9% |
| May 7, 2026 | $0.59 est $0.50 | $3.52B est $3.36B | +7.6% |
| Feb 26, 2026 | $0.57 est $0.52 | $3.70B est $3.53B | −7.2% |
| Nov 6, 2025 | $0.67 est $0.62 | $3.76B est $3.62B | −5.9% |
| Aug 7, 2025 | $0.62 est $0.56 | $3.58B est $3.47B | +10.9% |
| May 8, 2025 | $0.50 est $0.49 | $3.25B est $3.24B | +2.0% |
| Feb 27, 2025 | $0.54 est $0.57 | $3.53B est $3.60B | −17.9% |
| Nov 7, 2024 | $0.75 est $0.68 | $3.74B est $3.72B | +11.6% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Viatris is $21.00, +0.9% from the last close, from 9 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 9 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 13 | Barclays | $25 | +20.1% |
| Nov 9 | UBS | $28 | +34.5% |
| Nov 6 | J.P. Morgan | $21 | +0.9% |
| Nov 6 | UBS | $28 | +34.5% |
| Oct 26 | Piper Sandler | $14 | −32.8% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Viatris averaged +1.5% across the last 5 years, rising in 2 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −1.9% | 2 of 5 |
| Next 10 trading days | −2.8% | 1 of 5 |
| Next 15 trading days | −1.7% | 2 of 5 |
| Next 20 trading days | +1.5% | 2 of 5 |
| Next 30 trading days | +4.5% | 2 of 5 |
For scale, VTRS’s typical 20-trading-day move in either direction is about 6.7%.
Viatris’s market cap is $23.87B and revenue of $14.73B over the last twelve months.
Coverage of Viatris this week reads positive: 6 positive, 6 neutral and 1 negative headlines.
Viatris’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 24.0% above |
| JNJJohnson & Johnson | Neutral | 4.4% above |
| ABBVAbbVie | Neutral | 23.7% above |
| MRKMerck | Neutral | 8.2% below |
| AZNAstraZeneca | Neutral | 34.6% below |
| PFEPfizer | Accumulation | 8.9% below |
A peer links to its own page where one exists.
Viatris’s market cap is $23.87B at the Nov 13, 2026 close of $20.82, with 1.15B shares outstanding.
The consensus analyst 12-month price target for Viatris is $21.00, +0.9% from the last close. Of the 9 firms that rated the stock in the last 90 days, 5 rate it a buy, 3 a hold and 1 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Viatris is overvalued: the Nov 13, 2026 close of $20.82 is 7.8% above Gekko Fair Value of $19.31. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Viatris is expected to report on Feb 25, 2027, before the market opens (102 days away). Analysts expect earnings of $0.60 per share on revenue of $3.76B. Viatris beat the earnings estimate in 7 of its last 8 reports, moving 8.8% on average across the report.
Viatris’s 52-week high is $21.20 and its 52-week low is $10.15; it closed at $20.82 on Nov 13, 2026, +89.1% over the past year.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (trend and earnings risk), 2 as mixed (gekkoindex and seasonality) and 1 as a headwind (fair value). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.